Several studies have reported the association between hypomethylation of F2RL3 in the whole blood and the prognosis of CHD or increased risk of cardiovascular-related mortality, but so far there is no report about the methylation of F2RL3 in blood and the diagnosis of CHD (Breitling et al., 2012; Zhang et al., 2014b; Zhang et al., 2017; Gao et al., 2018). Here, F2RL3 is linked to coronary artery disorder.